SL-901
/ UCB, Menarini
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 09, 2025
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Terminated | Sponsor: Stemline Therapeutics, Inc. | Completed ➔ Terminated; The study was stopped after careful consideration of the landscape of similar drugs and evolving standard of care.
Trial termination • Oncology • Solid Tumor
July 12, 2023
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=20 | Completed | Sponsor: Stemline Therapeutics, Inc. | Recruiting ➔ Completed | N=60 ➔ 20 | Trial completion date: Dec 2023 ➔ Jun 2023 | Trial primary completion date: Dec 2023 ➔ May 2023
Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1